Vildagliptin/Empagliflozin/Metformin Hydrochloride

维格列汀/恩格列净/盐酸二甲双胍

Report date: 2025/11/26 20:00:44

Base Information

Drug NameVildagliptin/Empagliflozin/Metformin Hydrochloride
Drug Alias Name维格列汀恩格列净二甲双胍缓释片
ClassificationSmall molecules
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsDipeptidyl peptidase IVSodium/glucose cotransporter 2Protein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes VildagliptinEmpagliflozinMetformin Hydrochloride
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTaizhou Overseas Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaizhou Overseas Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A